Background:
Subjects with MS have lower adiponectin and higher PAI-1 levels compared to healthy controls. Lifestyle measures have been shown to improve the various components of MS, and hence there is an urgent need for public health measures to prevent the ongoing epidemic of diabetes and CVD.
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AbstractINTRODUCTIONMATERIAL AND
METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCESINTRODUCTION
The clustering of cardiovascular risk factors that includes central adiposity, hypertension, hyperglycemia, and high triglycerides (TG) with low high density lipoprotein cholesterol (HDL-C) levels is termed the metabolic syndrome (MS). MS is known to strongly predict the long-term risk of diabetes and cardiovascular disease (CVD). [1] Obesity can be said to be the predominant driving force behind the MS. [2] Adipose tissue products are reported to affect systemic metabolism; among these are adiponectin, leptin, plasminogen activator inhibitor-1 (PAI-1), resistin, inflammatory cytokines, and angiotensinogen. [3] Adiponectin has recently attracted much attention with particular emphasis on the role of adiponectin in the regulation of insulin sensitivity and the development of insulin resistance. [4] Plasma levels of adiponectin have also been reported to be significantly reduced in obese humans. [5] Moreover, plasma adiponectin levels have been shown to be decreased in patients with type-2 diabetes mellitus (T2DM), CVD, hypertension, and MS. [6] [7] [8] [9] Adiponectin activates adenosine mono-phosphate activated protein kinase and peroxisome proliferator activated receptor-in the liver and skeletal muscle, thereby stimulating phosphorylation of acetyl-CoA carboxylase, fatty acid oxidation, thus decreasing tissue triglyceride (TG) content in muscle and liver. These alterations increase insulin sensitivity in vivo. [3, 4] The expression levels of AdipoR1/R2 are also decreased in obesity, which reduces adiponectin sensitivity and finally leads to insulin resistance, the so-called "vicious cycle." [10] Adiponectin was demonstrated to strongly inhibit the expression of adhesion molecules, including intracellular adhesion molecule- where FI = fasting insulin in μIU/ml and G = fasting glucose in mmol/l.
The study was approved by the ethics committee of Army Hospital (Research and Referral), Delhi Cantt, and all subjects gave written informed consent.
Statistical analysis was carried out using EPI INFO 3.5.3 (CDC; Atlanta; USA). Data were presented as mean ± SD or number (%) unless specified. 
METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCESRESULTS
This study was carried out in 50 cases of MS and 24 normal healthy controls. Sex ratio was equal in both the groups. Basal characteristics of the cases and controls are shown in Table 1 (also given in our previous publication). [18] Mean ages of cases and controls were comparable. All cases had significantly higher WHR than controls in both the sexes. BMI¸ BFM and PBF were significantly higher in cases than controls. However, cases had significantly lower BMR than controls. There were 37 (74%) cases with T2DM and 13 (26%) cases with impaired glucose tolerance. Hypertension was present in 26 cases (52%). TG¸ total cholesterol (TC)¸ low density lipoprotein (LDL)¸ and very low density lipoprotein (VLDL) were significantly higher and HDL was significantly lower among cases than in controls. However¸ 14 controls (58%) also had low HDL.
Most of the cases (28.56%) had four features of MS, followed by cases with all features (16.32%), and 6 (12%) cases had three features of MS [ Table 1 ].
Adiponectin
Subjects with MS had significantly lower adiponectin levels than controls (4.01 ± 2.24 vs. 8.7 ± 1.77 μg/ml; P < 0.0001) [ Table 1 ]. Adiponectin levels decreased with increasing number of metabolic abnormalities [ Figure 1 ]. There was no difference in adiponectin levels between sexes (5.23 ± 3.12 vs. 5.71 ± 2.65 μg/ml; P = 0.49).
In univariate regression analysis, adiponectin was negatively associated with age, BMI, BFM and PBF, and positively associated with BMR. Among the various parameters of MS, adiponectin was negatively associated with all parameters, except HDL-C with which it was positively associated. There was no association between adiponectin and LDL-C. Adiponectin showed strong negative association with inflammatory markers (CRP, fibrinogen) and procoagulant marker (PAI-1). Adiponectin was positively associated with insulin secretion (HOMA-S) and negatively associated with insulin resistance (HOMA-IR) [ Table 2 ].
Multiple regression analysis showed that among the metabolic parameters, WHR, FPG and TG maintained negative association with adiponectin even after adjustment for all metabolic variables. However, HDL and hypertension lost significance during multiple regression analysis [ Table 3 ]. Only BMI remained negatively associated with adiponectin when adjusted for anthropometric parameters, e.g. BMR, BFM, and percent body fat, in multiple regression analysis [ Table 4 ]. BMR showed positive association when adjusted with BMI, but lost significance when BFM was added. Similarly, PAI-1 levels showed strong negative association with adiponectin [ Figure 2 ] even after adjustment with other parameters like HOMA-IR, CRP, and fibrinogen [ Table 5 ].
Receiver operating characteristic (ROC) curve analysis revealed best prediction value of adiponectin at 6.7 μg/ml with a sensitivity of 83%, specificity of 86%, accuracy of 85%, positive predictive value of 74%, negative predictive value of 84% and positive and negative likelihood ratios of 5.95 and 0.19, respectively (ROC 0.934, SE 0.0277, 95% CI = 0.879-0.988).
Plasminogen activator inhibitor-1
Subjects with MS had significantly higher PAI-1 levels than controls (53.85 ± 16.45 vs.
17.35 ± 4.45 ng/ml; P < 0.0001) [ Table 1 ]. PAI-1 levels increased with increasing number of metabolic abnormalities [ Figure 3 ]. There was no difference in PAI-1 levels between sexes (8.59 ± 4.42 vs. 8.21 ± 4.44 ng/ml; P = 0.71).
In univariate regression analysis, PAI-1 was positively associated with BMI, BFM and PBF, and negatively associated with BMR. Among the various parameters of MS, PAI-1 was positively associated with all parameters of MS, except HDL with which it was negatively associated. PAI-1 showed strong positive association with inflammatory markers (CRP, fibrinogen), insulin resistance (fasting plasma insulin and HOMA-IR) and total and LDL cholesterol, but had strong negative association with adiponectin [ Table 2 ].
Multiple regression analysis of various metabolic parameters showed that WHR and TG maintained positive association with PAI-1 even after adjustment for all metabolic variables. However, HDL, FPG and hypertension lost significance during multiple regression analysis [ Table 3 ]. Only PBF remained positively associated with PAI-1 when adjusted for anthropometric parameters, e.g. BMR, BFM, and BMI, in multiple regression analysis [ Table 4 ]. Similarly, PAI-1 levels showed strong positive association with fibrinogen even after adjustment with other parameters like HOMA-IR, CRP, and fibrinogen [ Table 5 ].
ROC curve analysis revealed best prediction value of PAI-1 at 25.0 ng/ml, with a sensitivity of 92%, specificity of 96%, accuracy of 95%, positive predictive value of 92%, negative predictive value of 96% and positive and negative likelihood ratios of 22.9 and 0.08, respectively (ROC 0.975, SE 0.0178, 95% CI = 0.942-1.009). 
METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCESDISCUSSION
MS is known to strongly predict long-term risk of diabetes and CVD, and has also been reported to be associated with increased morbidity and mortality. [1] It is becoming increasingly common in the United States and worldwide, and is emerging as the dominant risk factor for CVD in Asia. [2, 11, 20] The MS represents a combination of risk determinants, which include atherogenic dyslipidemia, elevated blood pressure, elevated glucose, a prothrombotic state, and a proinflammatory state. [1] In obese persons, adipose tissue products are reported to affect systemic metabolism; among these are adiponectin, leptin, inflammatory cytokines, PAI-1, resistin, and angiotensinogen. [3] In this study, we evaluated 50 subjects with MS (25 males between the present study and other studies. In this study, adiponectin showed no relation with fasting insulin levels, as also observed by one study from South India, [16] whereas others have reported negative correlation. [26, 31, 36] We have observed negative correlation of cholesterol with adiponectin, similar to that reported by Bilgili et al. [15, 26] But others [16, 31, 37] found no relation of adiponectin with TC. Vikram et al., [17] did not observe any relation between adiponectin and hsCRP in post-pubertal Asian Indian adolescents, as seen by us. Multiple regression analysis of the metabolic parameters showed WHR, FPG and TG to have an independent negative association with adiponectin even after adjustment for all metabolic variables. Yang et al., [31] observed positive association of HDL with adiponectin in multiple regression analysis.
However, in our study, HDL and hypertension lost significance during multiple regression analysis. Ku et al., [36] reported correlation between serum adiponectin and BMI, triglyceride, HDL-C and fasting glucose in multiple regression analysis. In the present study, only BMI remained negatively associated with adiponectin when adjusted for anthropometric parameters, e.g. BMR, BFM, and PBF, in multiple regression analysis. Jung et al., [38] showed significant negative correlation of adiponectin levels with percent body fat, lipid profile and HOMA-IR. BMR showed positive association when adjusted with BMI, but lost significance when BFM was added. Similarly, PAI-1 levels showed strong negative association with adiponectin even after adjustment with other parameters like HOMA-IR, CRP, and fibrinogen. Bilgili et al., [26] also found an inverse relationship between plasma adiponectin and PAI-1 (r = -0.653, P < 0.001).
ROC curve analysis revealed best prediction value at 6.7 μg/ml, with a sensitivity of 83%, specificity of 86%, and accuracy of 85%. Mohan et al., [15] also reported similar adiponectin levels (5.0 μg/ml for males and 6.5 μg/ml for females) in a study from South India. However, studies from Japan have suggested lower cut-off point (4 μg/ml) of serum adiponectin level for the diagnosis of MS. [29, 35] There is wide geographic variation in the adiponectin levels reported in literature. Seino et al., [32] also suggested that measuring adiponectin may be effective for evaluating the presence of MS in nondiabetic subjects through analysis of area under the curve of ROC curves.
Subjects with MS had significantly higher PAI-1 levels than controls, which is similar to that reported in many studies in the literature. [13, 26, [39] [40] [41] [42] [43] [44] [45] ] However, PAI-1 level was higher in the present study than that reported from other ethnic populations. Indian population has higher PAI-1 compared to African population, which is explained by the increased frequency of PAI-1 4G allele. [42] PAI-1 levels increased with increasing number of metabolic abnormalities. Similar observations have been made in other studies. [27, 39, 43, 46] In univariate regression analysis, PAI-1 was positively associated with BMI, BFM and PBF, and negatively associated with BMR. Among the various parameters of MS, PAI-1 was positively associated with all parameters of MS, except HDL with which it was negatively associated. PAI-1 showed a strong positive association with inflammatory markers (hsCRP, fibrinogen), insulin resistance (fasting plasma insulin, HOMA-IR) and total and LDL cholesterol, but had strong negative association with adiponectin. Others have also reported significant correlation between PAI-1 and all obesity and dyslipidemia variables. [27, 47] TG and WHR were independently associated with PAI-1 even after adjustment for all metabolic variables in multiple regression analysis. Greyling et al., [40] also found waist circumference as the strongest independent predictor of PAI- Tables   Table 1 Basic characteristics of cases and controls
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